Forward-looking statements and Non-GAAP financial measures

Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company.

FORWARD-LOOKING STATEMENTS AND DISCLAIMERS

These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements. All third-party marks—® and ™—are the property of their respective owners. Certain market and industry data has been obtained from third-party sources, which the Company believes are reliable, but the Company has not independently verified the information provided by third-party sources. Unless otherwise noted, market growth rates used in this presentation are estimates based on Company and third-party industry research.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. Definitions of the non-GAAP financial measures and a reconciliation of the GAAP to non-GAAP financial results are provided in the Appendix to this presentation.

The Company does not provide forward-looking guidance on a GAAP basis as the company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, real estate optimization and transformation initiatives, certain litigation charges and loss contingencies, costs related to acquisitions/divestitures and the related amortization, impairment and related charges, and other adjustments. For example, stock-based compensation may fluctuate based on the timing of employee stock transactions and unpredictable fluctuations in the company's stock price. Any associated estimate of these items and its impact on GAAP performance could vary materially.
Revealing the power of genetic science – for everyone

Mission
We advance health and well-being for all, empowering every individual by revealing the answers inside each of us.

Vision
As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health and enable healthcare providers to better detect, treat and prevent disease.
Myriad Genetics at-a-glance

A leader in genetic testing
Established franchises in hereditary cancer, pharmacogenomics, and prenatal testing

30+ years of scientific and commercial achievements
1,000+ scientific publications and counting

45,000+ active ordering healthcare providers
70 net promoter score
~2,700 employees

10%+ revenue growth year-over-year for fifth consecutive quarter
Commercial execution driving volume growth; price stability

Market-leading gross margins; healthy balance sheet

Innovation in ‘24 and beyond
Expect to launch multiple differentiated tests in prenatal and oncology

1. As of December 31, 2023
2. As of 4th quarter, 2023
3. As of December 2023 and excludes contribution from change of revenue estimates
Serving a more patient-centric healthcare system: Myriad Genetics’ overarching goals

Innovating in precision medicine to detect disease, support treatment decisions and improve clinical outcomes

Develop best-in-class test quality and scientific insights

- Industry-leading R&D delivers critical prenatal insights earlier in pregnancy than ever before
- Combined, MyRisk® Hereditary Cancer Test + RiskScore® is a more accurate predictor of cancer risk than Tyrer-Cuzick*
- Breakthrough science and clinical studies address the growing mental health crisis

Ease of use for patients and healthcare providers

Removing friction

- Epic EMR integration enables 600,000+ HCPs to order Myriad tests
- Telemedicine and chatbot platforms to meet patients where they are
- Enhancing portals for better experience in ordering and reporting by providers

Improving access for all and reducing healthcare costs

Serve more patients by broadening adoption and access

- Patient outreach to support underserved populations and ethnicities
- New point-of-care financial accessibility tools and payment programs

*Hughes et al., 2021 https://ascopubs.org/doi/10.1200/PO.20.00246
Innovation collaboration: Partnering with leading healthcare visionaries
Acquired Intermountain Precision Genomics' laboratory, together with Precise Tumor and Precise Liquid

Jan 18th
Deal Announced

Feb 1st
Deal closed - Myriad acquired
- Precise Tumor & Liquid Assay
- 35 Employees
- Equipment

Q2 Transition Planning -
- Start to move non-production equipment
- Improving processes and tech applications

Q2

Q4
- Move Precise Tumor production to Salt Lake Campus West

Q3

Q1

Precise Liquid
Molecular Profile Test
Precise Liquid
Q3 targeted launch at Salt Lake Campus West
3 focus areas: Oncology, Women's Health and Pharmacogenomics

**Oncology**
Clarifying cancer treatment with genetic and genomic insights and companion diagnostic tests that are designed to work with corresponding drugs and treatments.

<table>
<thead>
<tr>
<th>Oncologist</th>
<th>Surgeon</th>
<th>Urologist</th>
<th>Genetic Counselor</th>
</tr>
</thead>
<tbody>
<tr>
<td>OB/GYN</td>
<td>Maternal Fetal Medicine</td>
<td>Primary Care</td>
<td>Genetic Counselor</td>
</tr>
</tbody>
</table>

**Women’s Health**
A leader in health and wellness with differentiated genetic insights for women of all ancestries, assessing cancer risk and offering prenatal solutions.

<table>
<thead>
<tr>
<th>Psychiatrist</th>
<th>Primary Care</th>
<th>Nurse Practitioner/Physician Assistant</th>
</tr>
</thead>
</table>

**Pharmacogenomics**
Using genetic insights to help physicians understand how genetic alterations impact patient response to antidepressants and other drugs.

<table>
<thead>
<tr>
<th>MyRisk® Hereditary Cancer Test</th>
<th>MyChoice® CDx Myriad HRD Companion Diagnostic Test</th>
<th>MyRisk® with RiskScore® for all ancestries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prolaris® Prostate Cancer Prognostic Test</td>
<td>BRACAnalysis CDx® Gemline Companion Diagnostic Test</td>
<td>FirstGene™ Multiple Prenatal Screen</td>
</tr>
<tr>
<td>EndoPredict® Breast Cancer Prognostic Test</td>
<td>Precise® Tumor Molecular Profile Test</td>
<td>Foresight® Carrier Screen</td>
</tr>
<tr>
<td>2024E Launch expected</td>
<td>2025E Launch expected</td>
<td>2025E Launch expected</td>
</tr>
<tr>
<td>Precise® Liquid Molecular Profile Test</td>
<td>Precise® MRD Molecular Residual Disease Monitoring</td>
<td>Prequel® Prenatal Screen</td>
</tr>
<tr>
<td>GeneSight® Mental Health Medication Test</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

©2024 Myriad Genetics, Inc.
# Diversified portfolio within large, fragmented, actionable markets

<table>
<thead>
<tr>
<th>Actionable Market Opp.</th>
<th>Oncology</th>
<th>Women’s Health</th>
<th>PGx</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AFFECTED HCT + GERMLINE</td>
<td>TUMOR PROFILING&lt;sup&gt;3&lt;/sup&gt;</td>
<td>MRD</td>
</tr>
<tr>
<td>$1.2B</td>
<td>$500M</td>
<td>$20B+</td>
<td>$350M</td>
</tr>
<tr>
<td>Market Penetration</td>
<td>~65%</td>
<td>~45%</td>
<td>&lt;5%</td>
</tr>
</tbody>
</table>

| Myriad Products        |          |                |                |                |                |
|------------------------|----------|----------------|----------------|----------------|
| MyRisk<sup>2</sup>     | BrACAnalysiScDx<sup>2</sup> | Precise<sup>2</sup>Tumor | Precise<sup>2</sup>MRD | MyChoice<sup>2</sup>CDx | Prolaris<sup>2</sup> |
| MyRisk<sup>2</sup>     | BrACAnalysiScDx<sup>2</sup> | Precise<sup>2</sup>Liquid | MyChoice<sup>2</sup>CDx | Prolaris<sup>2</sup> |
| Foresight<sup>2</sup> | Prequel<sup>2</sup> | SneaKPeek<sup>2</sup> | MyRisk<sup>2</sup> | GeneSight<sup>2</sup> |

- **>$30B** of actionable market opportunity
- **<40%** average market penetration across all categories
- **<20%** of market share concentrated among Top 3 players
- **Myriad holds Top 3 position** in 6 out of 7 active product categories

<sup>1</sup>: Actionable market indicated against cancers of commercial focus  
<sup>2</sup>: In ovarian, breast, prostate, and pancreatic cancers only  
<sup>3</sup>: Reflective of IHC partnership  
Data as of 2022 from third-party global consulting firm and internal estimates.
Significant opportunity to accelerate MyRisk growth across Women’s Health, Imaging, Oncology and Urology

Roadmap of expected highlights

2024
- MyRisk patient portal
- MyRisk Medical Management Tool Enhancements
- RiskScore studies
- Breast Cancer Risk Assessment Program

2025
- Panel Expansion | WES (whole exome sequencing)
- BRAC CDx to NGS

Figures in thousands

Q4 ’22: +16%
Q1 ’23: +24%
Q2 ’23: +20%
Q3 ’23: +18%
Q4 ’23: +8%

2023 LTM Volume Growth (YOY) +17%
Strong commercial execution driving significant volume growth in the last twelve months

**Roadmap of expected highlights**

**2024**
- Health Economic Outcome Research (HEOR) study***
- Significant opportunity to improve payor coverage and ASP

**2025**
- Postpartum Clin Dev Protocol & Study

---

**Figures in thousands**

<table>
<thead>
<tr>
<th>Quarter</th>
<th>YOY Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4 '22</td>
<td>+22%</td>
</tr>
<tr>
<td>Q1 '23</td>
<td>+31%</td>
</tr>
<tr>
<td>Q2 '23</td>
<td>+23%</td>
</tr>
<tr>
<td>Q3 '23</td>
<td>+19%</td>
</tr>
<tr>
<td>Q4 '23</td>
<td>+21%</td>
</tr>
</tbody>
</table>

---

**Actionable market size (US only)**
- ~$5B

**Market penetration**
- 15%

**Market growth**
- Mid teens

**MYGN market share**
- 55-60%

---

***This study used data from the Optum Labs Data Warehouse, composed of de-identified administrative claims data for both commercially insured and Medicare Advantage enrollees. The claims data were linked on a de-identified basis with PGx test results.

---

*Data as of 2022 from third-party global consulting firm and internal Company estimates

**Expected

©2024 Myriad Genetics, Inc.
Strong runway for Prolaris with an opportunity to capture more market share with compelling updates

Roadmap of expected highlights

2024  Expanded coverage from UnitedHealthcare
       ARR (Absolute Risk Reduction) report
       Publish 3-yr Metastasis study

2025  Prolaris Post-RP launch

Actionable market size (US only)*  Market penetration*  Market growth**  MYGN market share*

~$600M  35%  Low teens  ~40%

*Data as of 2022 from third-party global consulting firm and internal Company estimates
**Expected

Figures in thousands

2023 LTM Volume Growth (YOY)

<table>
<thead>
<tr>
<th>Quarter</th>
<th>YOY Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4 '22</td>
<td>+17%</td>
</tr>
<tr>
<td>Q1 '23</td>
<td>+22%</td>
</tr>
<tr>
<td>Q2 '23</td>
<td>+13%</td>
</tr>
<tr>
<td>Q3 '23</td>
<td>+9%</td>
</tr>
<tr>
<td>Q4 '23</td>
<td>+4%</td>
</tr>
</tbody>
</table>
A market that continues to grow with potential tailwinds from guideline expansion

<table>
<thead>
<tr>
<th>PREQUEL</th>
<th>FORESIGHT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actionable market size (US only)*</td>
<td>~$1.3B</td>
</tr>
<tr>
<td>Market penetration*</td>
<td>45-55%</td>
</tr>
<tr>
<td>Market growth**</td>
<td>Low single digits</td>
</tr>
<tr>
<td>MYGN market share*</td>
<td>Low-to-mid teens</td>
</tr>
<tr>
<td>Market growth**</td>
<td>Mid teens</td>
</tr>
</tbody>
</table>

*Data as of 2022 from third-party global consulting firm and internal Company estimates

**Expected

Roadmap of expected highlights

2024 Foresight on NovaSeq
Various Prequel studies
Foresight Universal Plus

2025 FirstGene Launch

Figures in thousands

2023 LTM Volume Growth (Y/Y)

<table>
<thead>
<tr>
<th>Year</th>
<th>Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4 '22</td>
<td>(1%)</td>
</tr>
<tr>
<td>Q1 '23</td>
<td>+12%</td>
</tr>
<tr>
<td>Q2 '23</td>
<td>+12%</td>
</tr>
<tr>
<td>Q3 '23</td>
<td>+20%</td>
</tr>
<tr>
<td>Q4 '23</td>
<td>17%</td>
</tr>
</tbody>
</table>

©2024 Myriad Genetics, Inc.
Pillars of long-term growth and profitability

**Science and innovation**
Top-tier science delivering products that are clinically validated and demonstrate proven utility (quality, access and cost) in real world clinical settings.

**Elevated customer experience and commercial execution**
Strong digitally enabled commercial platform.

**Technology enabled operations**
Automated, scalable and cost-effective laboratory operations and technology platform.

**Scalable commercial, lab operations and administrative support services**
Advanced regulatory, reimbursement, and revenue cycle capabilities.
# 3-year product roadmap summary of clinical validity/utility and ease of use enhancements

<table>
<thead>
<tr>
<th></th>
<th>2023</th>
<th>2024E</th>
<th>2025E</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MyRisk</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hereditary Cancer Test</td>
<td>Tyner-Cuzick v8</td>
<td>MyRisk patient portal</td>
<td>MyRisk Panel expansion</td>
</tr>
<tr>
<td><strong>Prolaris</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate Cancer Prognostics Test</td>
<td>ARR</td>
<td>3-year Mets Study</td>
<td></td>
</tr>
<tr>
<td><strong>Foresight</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Center Screen</td>
<td>Foresight Universal Plus</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FirstGene</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple Prenatal Screen</td>
<td>Validation</td>
<td>Study</td>
<td>Full Launch</td>
</tr>
<tr>
<td><strong>Precise Liquid</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Molecular Profile Test</td>
<td>Launch</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Precise MRD</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Molecular Residual Disease Monitoring</td>
<td>RUO (Research Only)</td>
<td>Pharma Availability</td>
<td>Comm’l Launch</td>
</tr>
<tr>
<td><strong>MyChoice CDx</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myriad HRD Companion Diagnostic Test</td>
<td>Indication Expansion (e.g. Breast and Prostate)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GeneSight</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mental Health Medication Test</td>
<td>Psych 4.3</td>
<td>Psych 4.4</td>
<td></td>
</tr>
</tbody>
</table>
Active expansion of high-quality testing pipeline, addressing real-world community needs

### Women’s Health

**FirstGene™**
Multiple Prenatal Screen

- Integrated assay for NIPS + carrier screen + fetal recessive status + fetomaternal blood compatibility on a single blood draw on one person.

- Faster turnaround time
- 3x lower cost of goods
- Established reimbursement

---

**Foresight®**
Universal Plus panel

- Pioneering expanded carrier screen that uses NGS to find pathogenic variants underlying recessive disease.

- Merged couple reporting
- Fully automated lab workflow drives low COGS

---

### Oncology

**Precise™ Tumor**
Robust tumor profiling & therapy selection

- Pan-cancer comprehensive genomic profiling test using Illumina TruSight Oncology 500; may serve as first-line offering.

- Panel size ~2x size (500 genes) of lead competitor; uses both DNA/RNA; ease of use as part of Precise Oncology Solutions
- Established reimbursement path

---

**Precise™ Liquid**
Robust tumor profiling & therapy selection

- Comprehensive genomic profiling test; may serve as first-line offering or as reflex if solid tumor is insufficient.

- Panel size ~2x size (500 genes) of lead competitor; uses DNA; ease of use as part of Precise Oncology Solutions
- Established reimbursement path

---

**Precise™ MRD**
Molecular residual disease monitoring

- Monitoring test based on whole genome sequencing to deeply interrogate tumor, detect recurrence earlier and help guide treatment decisions.

- Targets 10x variants
- Known path to reimbursement

---

* Research Use Only
Transformative prenatal screen running multiple tests at once

Current PROBLEMS with prenatal genetic screening

- Providers don’t have enough time to talk about genetics
- Only 50% utilization of carrier screening
- Only 30% of fathers get screened when mother is a carrier
- Low gross margins on NIPS and ECS

New SOLUTION

FirstGene™
Multiple Prenatal Screen

- Easier for providers to administer integrated offering
- No need to screen the father
- Estimated 30-40% higher gross margins compared to Foresight or Prequel alone
Key Additions to the Oncology Portfolio, set stage for MRD Launch to follow

**Precise™ Tumor**
Robust tumor profiling & therapy selection

**What is It?**
Pan-cancer comprehensive genomic profiling test using Illumina TruSight Oncology 500; may serve as first-line offering

**Key Advantages**
- Panel size ~2x size (500 genes) of lead competitor; uses DNA; ease of use as part of Precise Oncology Solutions
- **Reimbursed**

---

**Precise™ Liquid**
Robust tumor profiling & therapy selection

**What is It?**
Comprehensive genomic profiling test; may serve as first-line offering or as reflex if solid tumor is insufficient

**Key Advantages**
- Panel size ~2x size (500 genes) of lead competitor; uses DNA/RNA; ease of use as part of Precise Oncology Solutions
- **LCD Submitted Dec.’ 23**

---

**Strategic Value of Precise Tumor & Precise Liquid**
- A successful Oncology franchise will help medical oncologist select treatments for their patients
- Precise Tumor will complement MyChoice CDx providing physicians with Comprehensive Gene Panel data to inform treatment decision
- Precise Liquid will help physicians who experience solid tumor test failures or do not have adequate tumor samples for testing obtain treatment guidance
- Precise Liquid will offer easier sample collection and sample type synergy with MyRisk and Precise MRD
- Precise Tumor and Precise Liquid will strengthen medical oncology experience to support the Launch of Precise MRD
Differentiation built upon existing competencies

Tumor + normal sample prep and sequencing  Bioinformatic identification of somatic variants  cfDNA isolation and targeted sequencing  Detect presence or absence of tumor cfDNA

Comparable Myriad test
- MyChoice® CDx
- Myriad HRD Companion Diagnostic Test
- FirstGene®
- Multiple Prenatal Screen

Existing and proprietary* chemistry and technology

More Targeted tumor sites increases sensitivity
- Competitor: 16 sites
- Myriad: 1000 sites

Monitoring Test Economics - Gross Margin (Est.) per Patient
- 1st sample (Tumor + Blood)
- 2nd (Blood)
- 3rd (Blood)
- 4th+ sample (Blood)

Higher sensitivity: detection at 10x lower tumor levels
100x more of the genome explored
Over 60x more targeted sites
Earlier detection of recurrence

*patients pending
Improving the patient and provider experience

Myriad aims to simplify and streamline the genetic screening and testing process. It respects patient privacy, is easy to implement, and provides support at every step.

Top 5 Dx test provider requirements

- Strong clinical validity and utility
- Comprehensive product offering / menu
- Fast turnaround times
- Ease of use in ordering and report utilization
- Affordability for the patient
## Enterprise infrastructure: investing for flexibility and scale

### Product Platform

<table>
<thead>
<tr>
<th>Period</th>
<th>2022</th>
<th>2023</th>
<th>2024E</th>
<th>2025E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Q2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Q3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Q4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Advanced Sequencing Transitions (Novaseq)**
  - Prenatal
  - MyChoice CDx
  - BRACAnalysis CDx

- **Whole Exome**
  - For Oncology and Pharma applications

### Facilities

- **New Facility Construction**
  - South San Francisco innovation campus construction
  - Salt Lake City production lab campus construction

- **Shift Operations to New Facilities**
  - Transition Innovation operations to new South San Francisco facility
  - Transition Salt Lake City Research Park products to new campus

### Operations

- **Advanced Lab Automation**
  - 1st phase of Salt Lake City automation
  - MyRisk and CDx automation

- **Commercial Enablement**
  - SalesForce CRM

- **EMR integrations**
  - Bi-directional, all-digital EMR integrations

- **Revenue Cycle**
  - Orchestration & Robotic Process Automation
  - Advanced Automation & AI

* >85% of investment is estimated to be capitalizable expense
Full year and fourth quarter 2023 operating and financial highlights

Full-Year 2023 Revenue Growth Driven by All Three Business Units

- **+11% YOY**
  - Revenue Growth by Unit:
    - **+15%** in Women's Health*
    - **+9%** in Pharmacogenomics
    - **+8%** in Oncology

Positive Q4’23 Adj. EPS and Adj. Operating Cash Flow

- **$0.04** Adj. EPS reflecting double-digit YOY revenue growth and cost management
- **$14 million** Adj. Operating Cash Flow; an increase of $10 million YOY

Raising 2024 Revenue Guidance: Healthy Balance Sheet

- Raising 2024 revenue guidance; introducing positive Adj. EPS guidance
- Raised **$118 million** net proceeds from equity offering; YE ’23 cash & equivalents balance of **$141 million**

Ongoing Investments in Strategic Growth Channels

- Acquired Precise Tumor and Liquid assets from partner Intermountain Health
- Excellent strategic fit; Enables more complete offering to the oncologist

* Excluding SneakPeek, 2023 Women’s Health revenue grew 9% YOY
2023 Operational highlights fueling our growth

Team Engagement

- 86% of our team rate Myriad as a “Great Place To Work”
- 9% Employee turnover, approximately half of what it was in 2021

Market Perception and Customer Service Levels

- 70 Net Promoter Score among current Myriad providers ordering across our testing portfolio (2023)
- 47% Of genetic counselors surveyed in 2023 had a more positive impression of Myriad because of our contributions to ClinVar*

Efficiency & Speed

- 6.0 days Rapid turn-around times critical for patients making time-sensitive care decisions
- +13% YOY sales productivity increase with structural optimization, automation and accelerating marketing demand (2023)

Revenue Cycle

- $+45M Revenue in excess of expectations (2021-2023) with fully enhanced revenue cycle platform
- 53 Days Industry leading Days Sales Outstanding (DSO) consistent with Q3 ‘23

All data as of fourth quarter, 2023, except as otherwise noted

* Brand Equity Research 2023. How does knowing that Myriad Genetics has begun sharing variant data classifications to public database ClinVar affect you feel about Myriad compared to their competitors?

** Excluding contribution from SneakPeak Early Gender DNA test
Hereditary cancer test, Prenatal and GeneSight volumes continue to drive performance in 2023

Select test volume and growth rates
All figures in thousands, except growth rates

Hereditary cancer testing (HCT) highlights:
- Sixth consecutive quarter of YOY growth in test volumes.
- 10% YOY growth in 4Q ‘23 HCT volumes in Women’s Health.
- 7% YOY growth in 4Q ‘23 HCT volumes in Oncology.

4Q ‘23 volume growth by product:
- 8% in Hereditary Cancer
- 17% in Prenatal*
- 21% in Pharmacogenomics
- 4% in Prolaris

* Excluding contributions from the SneakPeek® Early Gender DNA test
2023 financial progression by quarter

All figures in millions, except per share amounts and percentages

<table>
<thead>
<tr>
<th>Total revenue</th>
<th>Adjusted Gross Margin*</th>
<th>Adjusted Operating Expense*</th>
<th>Adjusted EPS*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4 '22</td>
<td>177.8</td>
<td>70.1%</td>
<td>138.6</td>
</tr>
<tr>
<td>Q1 '23</td>
<td>181.2</td>
<td>67.7%</td>
<td>133.4</td>
</tr>
<tr>
<td>Q2 '23</td>
<td>183.5</td>
<td>70.4%</td>
<td>137.3</td>
</tr>
<tr>
<td>Q3 '23</td>
<td>191.9</td>
<td>69.0%</td>
<td>130.0</td>
</tr>
<tr>
<td>Q4 '23</td>
<td>196.6</td>
<td>69.0%</td>
<td>144.5</td>
</tr>
</tbody>
</table>

2023 actual: $753

*GAAP to non-GAAP reconciliations can be found in the appendix.
### Raising 2024 revenue guidance; introducing adjusted EBITDA and EPS

All figures in millions, except per share amounts and percentages

<table>
<thead>
<tr>
<th>2024 FINANCIAL GUIDANCE</th>
<th>EXPECTED YEAR-OVER-YEAR CHANGE</th>
<th>2024 COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenue</td>
<td>$820 - $840</td>
<td>9% - 11%</td>
</tr>
</tbody>
</table>

- Raised 2024 revenue guidance range by $5 million for the full year.
- Q1 ‘24 revenue expected to grow at a mid-to-high single digit percentage rate year-over-year; and this growth rate is expected to accelerate throughout the rest of the year.

| Gross margin %          | 69.5% - 70.5%                   | 50 – 150 bps  |

- GM expected to fluctuate in any quarter given product mix, pricing trends and seasonality.
- Q1 ’24 GM expected to reflect typical seasonality, with Q1 ’24 margins lower than Q4 ’23 gross margins and ramping up throughout rest of 2024.

| Adjusted operating expenses* | $572 - $582 | 5% - 7% |

- Introducing adjusted EBITDA in the financial guidance table to provide additional insights into the earnings trajectory.

| Adjusted EBITDA* | $20 - $30 |

| Adjusted EPS*    | $0.00 - $0.05 | +$0.27 - $0.32 |

- Q1 ’24 adjusted EPS expected to be negative reflecting seasonality.

*The company does not forecast GAAP operating expenses, earnings before interest, tax, depreciation, or amortization (EBITDA), and earnings per share because it cannot predict certain elements that are included in reported GAAP results. See the statement on Non-GAAP Financial Measures at the beginning of this presentation and the Appendix to this presentation for more information about the use of non-GAAP financial measures.

Assumes currency rates as of February 27, 2024.
Annual revenue growth expected to accelerate to 10%+ in ‘24–‘26

Right to win with core products driving market share gains

Pipeline addresses large growth markets

Operating leverage, profitability, and positive cash flow

Capital deployment

Raised 2024 full-year revenue guidance to $820 - $840 million reflecting expected annual growth of 9-11% over 2023

Enhanced commercial execution generating double-digit volume growth as adoption rates and competitive position improves

Robust and differentiated product pipeline opens access to incremental multi-billion-dollar markets

Strength of business model, technology platform and enhanced laboratory capabilities expected to drive operating leverage, adjusted profitability and positive adjusted cash flow in 2024–2026

Disciplined capital deployment; continue to invest in high ROI opportunities within core channels

Well positioned to take advantage of future market opportunities